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Abstract
Background: Although antiretroviral therapy (ART) is known to be associated with time-dependent reductions in
tuberculosis (TB) incidence, the long-term impact of ART on incidence remains imprecisely defined due to limited duration
of follow-up and incomplete CD4 cell count recovery in existing studies. We determined TB incidence in a South African ART
cohort with up to 8 years of follow-up and stratified rates according to CD4 cell count recovery. We compared these rates
with those of HIV-uninfected individuals living in the same community.
Methodology/Principal Findings: Prospectively collected clinical data on patients receiving ART in a community-based
cohort in Cape Town were analysed. 1544 patients with a median follow-up of 5.0 years (IQR 2.4–5.8) were included in the
analysis. 484 episodes of incident TB (73.6% culture-confirmed) were diagnosed in 424 patients during 6506 person-years
(PYs) of follow-up. The TB incidence rate during the first year of ART was 12.4 (95% CI 10.8–14.4) cases/100PYs and
decreased to 4.92 (95% CI 3.64–8.62) cases/100PYs between 5 and 8 years of ART. During person-time accrued within CD4
cell strata 0–100, 101–200, 201–300, 301–400, 401–500, 501–700 and $700 cells/mL, TB incidence rates (95% CI) were 25.5
(21.6–30.3), 11.2 (9.4–13.5), 7.9 (6.4–9.7), 5.0 (3.9–6.6), 5.1 (3.8–6.8), 4.1 (3.1–5.4) and 2.7 (1.7–4.5) cases/100PYs, respectively.
Overall, 75% (95% CI 70.9–78.8) of TB episodes were recurrent cases. Updated CD4 cell count and viral load measurements
were independently associated with long-term TB risk. TB rates during person-time accrued in the highest CD4 cell count
stratum (.700 cells/mL) were 4.4-fold higher that the rate in HIV uninfected individuals living in the same community (2.7
versus 0.62 cases/100PYs; 95%CI 0.58–0.65).
Conclusions/Significance: TB rates during long-term ART remained substantially greater than rates in the local HIV
uninfected populations regardless of duration of ART or attainment of CD4 cell counts exceeding 700 cells/mL.
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Introduction
As the 2015 end-point for the Millennium Development Goals
approaches, HIV-associated tuberculosis (TB) remains a substantial
challenge to global health, accounting for 13% (1.1 million) of new
TB cases and approximately 25% of global deaths from HIV/AIDS
[1]. The greatest burden of disease is in the countries of sub-Saharan
Africa where approximately 80% of cases occur. In addition to the
DOTS TB control strategy, interventions to address HIV-
associated TB include isoniazid preventative therapy (IPT),
infection control, intensive case finding and antiretroviral therapy
(ART) [2–4]. However, ART remains the only TB preventative
intervention implemented on a large scale. By the end of 2009
treatment had been provided for 3.91 million people in sub-Saharan
Africa and to 0.97 million people in South Africa alone [5].
A meta-analysis of observational cohort studies reported a 67%
(95% CI 61–73) reduction in TB risk in patients receiving ART,
indicating its key role in prevention of HIV-associated TB [2,6].
High initial rates of TB in the first few months of ART rapidly
decrease with time-dependent reductions during the first 2–3 years
of treatment [7–15]. However, these data are limited. Median
follow-up is generally short and infrequently exceeds 2 years.
Calculation of long-term TB rates has therefore been based on
small numbers of participants and events, as reflected by wide
confidence intervals. Many patients included in these studies have
not attained their greatest potential CD4 cell count recovery, and
much person-time accrued is therefore associated with lower CD4
cell counts. Moreover, cases are often not microbiologically
proven. Thus, true long-term TB rates and risk factors remain
imprecisely defined.
Data on the incidence of TB during long-term ART and
comparisons with local HIV uninfected populations are important
for providing much needed insight into the likely long-term impact
of ART on the HIV-associated TB epidemic at a population level.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34156
Such data are also needed to inform the implementation of
additional preventive interventions. However, previously low rates
of HIV testing among TB patients in many settings has meant that
it has not been possible to accurately estimate the TB notification
rate in the HIV-uninfected sub-population in the relevant local
communities. In this study, we have substantially built on existing
findings in a large ART cohort in Cape Town, analysing data
from patients treated for up to 8 years and from patients who
attained very high levels of CD4 cell count recovery. We provide a
careful comparison of these rates with those measured among
HIV-uninfected adults living in the same local community, which
have not previously been available.
Methods
Study setting
This study was part of ongoing research at the Gugulethu ART
service in the Klipfontein sub-district of Cape Town, which has
been previously well described [16]. It has a predominantly
African population of over 300,000 who mostly live in low
socioeconomic conditions. At the time of programme commence-
ment, antenatal HIV seroprevalence was approximately 30% and
the annual TB notification rate was estimated to be greater than
1,500/100,000 [16–18].
Referrals were received from primary care clinics, antenatal
clinics and TB clinics. Programmatic criteria for starting ART
followed national guidelines, based on the 2002 WHO recom-
mendations, providing free ART for those with WHO stage 4
disease or a CD4 cell count ,200 cells/mL [19]. The first-line
ART regimen comprised of two nucleoside reverse transcriptase
inhibitors and a non-nucleoside reverse transcriptase inhibitor.
The second-line regimen included protease inhibitors. Patients did
not receive IPT as per national practice at that time.
Patients received routine clinical review at a screening visit,
treatment initiation, after 4, 8 and 16 weeks of ART, and
thereafter at least every 4 months. Patients had open access to the
clinic at all other times. Blood CD4 cell counts and plasma viral
load levels were done routinely at baseline and every four months.
Tuberculosis screening and diagnosis
TB screening was conducted at baseline using a symptom-
screening questionnaire to identify patients who required further
TB investigations. Investigations available to diagnose TB at
baseline or during ART included sputum induction, sputum smear
fluorescence microscopy, automated liquid culture of sputum using
mycobacterial growth indicator tubes (MGIT 960, Becton
Dickinson, Sparks, Maryland, USA), chest radiology, ultrasonog-
raphy and fine needle lymph node aspiration and cytology. All
microbiological specimens were analysed in accredited laborato-
ries, and all positive cultures were speciated by polymerase chain
reaction. TB treatment was rifampicin-based and under a directly
observed treatment short-course (DOTS) strategy provided
through a network of community clinics.
‘Incident TB’ was defined as a new clinical episode of TB
diagnosed after initiation of ART irrespective of date of symptom
onset. Diagnoses of ‘recurrent TB’ were made with reference to
any previous episodes of TB, including those made prior to ART
enrolment. All TB diagnoses fulfilled WHO criteria for resource-
constrained settings with high HIV prevalence [20]. Smear-
negative pulmonary TB, in addition to two sputum samples being
negative for acid-fast bacilli (AFB), was defined by radiological
abnormalities consistent with active TB, and either a positive
culture for Mycobacterium tuberculosis complex or a clinician’s
decision to treat with a full course of anti-tuberculosis chemother-
apy. Extrapulmonary TB was either culture or smear-positive from
an extrapulmonary site, or had strong histological or clinical
evidence of active TB with a clinician’s decision to treat with a full
course of anti-tuberculosis chemotherapy. Patients with both
pulmonary and extrapulmonary disease were classified as
extrapulmonary TB. For diagnoses of recurrent episodes of
incident TB during ART, patients must have completed a full
course of anti-tuberculosis treatment with resolution of symptoms.
Data collection and ethics
Data were collected from patients enrolled consecutively into
the ART programme from September 2002 until May 2006.
Patients were excluded if they did not initiate ART, were non-
naı¨ve to ART at enrolment due to transfer in from another service,
and if aged less than 16 years. Information on TB events was
obtained from prospectively maintained structured clinical rec-
ords. Laboratory results were transferred weekly to an electronic
database. All patients enrolled in the study gave written, informed
consent to participate. The collection of data on this study cohort
and use of data from the Cape Town TB register for research
purposes was approved by the Research Ethics Committee of the
University of Cape Town.
TB rates in the community
Community TB services were provided through the same local
clinics as for the study cohort, supported by a comprehensive
laboratory service. TB cases were recorded in an electronic TB
register as per South African national guidelines [21]. TB
notification data, including the HIV status of diagnosed cases,
for the local population (Klipfontein sub-district) was extracted
from the Cape Town electronic TB register. Data corresponding
to 2009 were used to calculate community rates as HIV status had
been determined for a high proportion (87%) of the TB
notifications in this year, which was also during the latter part of
the overall follow-up period by which time good immune recovery
would have occurred in patients recruited in earlier years.
Population and HIV prevalence data stratified by age, sex and
HIV status were obtained from the National Department of
Health/Health Information System Program and the Actuarial
Society of South Africa AIDS demographic model, respectively
[22–24]. These data were used to provide the necessary
numerators and denominators to calculate TB rates stratified by
HIV-status, age and gender as previously described [25].
Data analysis
Data were analysed using Stata version 11.0 (College Station,
Texas, USA). Person-time at risk of TB was accrued from the date
of starting ART until death, transfer, loss to follow-up (LTFU) or
censoring of observations on 1st January 2011. Any patient over 12
weeks late for a scheduled appointment who failed to return to the
ART programme and could not be located by community-based
follow-up was classified as LTFU. Person-time accrued during
treatment of prevalent or incident TB was excluded when
calculating TB incidence rates, and all episodes of incident TB
were included in the analysis. Chi-squared tests were used for
comparing proportions, t-tests for comparing means and Wilcoxon
rank-sum tests for comparing medians. All statistical tests were
two-sided at a value of 0.05.
Person-time was divided into intervals predefined by the CD4
count measurements done at least every 16 weeks. Each interval was
defined by the CD4 count and viral load at the start of the interval,
and categorised into CD4 cell count strata and viral load strata. If
CD4 cell count or viral load measurements were missing for one or
more intervals, a mean of the preceding and subsequent values were
TB during Long-Term ART in South Africa
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used (1.6% of all intervals). Poisson regression models were used to
calculate incidence rate ratios (IRR) with 95% confidence intervals
(CI) for time-updated and baseline characteristics. Random effects
modelling was used to account for clustering of person-time for
individuals with more than one episode of incident TB. A
multivariate model was constructed using Poisson regression and
based on forward selection; a priori risk factors (age and gender) and
variables identified as being associated with incident TB during the
univariate analysis were included. Likelihood ratio tests were used to
investigate interactions between variables, statistical hypotheses and
linear trends. TB incidence rates in the local community were
calculated using all TB notifications during 2009 and mid-year
population denominators from the same year stratified using HIV
prevalence data.
Results
Cohort characteristics
Of 2000 patients enrolled into the ART programme between
September 2002 and May 2006, a total of 456 were excluded
because they were aged less than 16 years (n = 161), non-naı¨ve to
ART (n = 85), died before starting ART (n = 91) or deferred from
starting ART for a variety of reasons (n = 119). 1544 (77.2%)
initiated ART and were included in the analysis (Figure 1). Of
Figure 1. Patient enrolment and outcomes during follow-up.
doi:10.1371/journal.pone.0034156.g001
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these patients, 208 (13.5%) died during ART, 318 (20.6%) were
LTFU and 207 (13.4%) were transferred to other ART services.
Median follow-up time for patients included in the analysis was
59.4 months (IQR 29.0–69.7; range 0.0–98.8), and a total of 6506
person-years (PYs) of follow-up were accrued after excluding time
on TB treatment.
The mean age of the cohort was 34 years, and the majority of
patients were women (70.1%). Overall, patients had advanced
immunodeficiency at enrolment with a median baseline CD4 cell
count of 98 cells/mL (IQR 48–155) (Table 1). Almost half of
patients (47.0%) had a past history of TB and had completed a
course of anti-tuberculosis treatment before starting ART.
Approximately one third (30.0%) of patients were receiving anti-
tuberculosis treatment (prevalent TB) at the time of ART
initiation. Characteristics did not differ for those alive and retained
in the cohort at data censorship and those transferred out or
LTFU, except those retained in the cohort had an older mean age.
TB diagnoses
Incident episodes of TB occurred among 424 (27.5%) patients
during ART. In total there were 484 episodes of incident TB, with
49 patients having 2 episodes and 5 patients having greater than 2
episodes of incident TB. For episodes where disease site was
recorded (98.8%), 362 (74.8%) were pulmonary TB and 116
(24.0%) were extrapulmonary TB. Overall, 73.6% (95% CI 69.4–
77.4) of TB episodes were confirmed by culture. Baseline
characteristics of those who were and were not diagnosed with
incident TB were similar (Table 1), except those with incident TB
were younger (p = 0.02), more likely to have had a history of TB
before ART initiation (p,0.001) and less likely to have been
receiving treatment for prevalent TB at the time of ART initiation
(p = 0.001). By data censorship, the cumulative proportion of
patients who had ever had a TB diagnosis (before or during ART)
was 75.4% (73.2–77.6).
TB incidence rates over time
The overall TB incidence rate during ART was 7.44 cases/100
PYs (95% CI 6.80–8.13). TB rates were highest in the first year of
ART at 12.43 cases/100 PYs (95% CI 10.82–14.35) and
decreased by almost half in the second year to 6.71 cases/100
PYs (95% CI 5.48–8.30) (Table 2). Thereafter, rates decreased to
4.92 (95% CI 3.64–8.62) cases/100 PYs beyond five years of
ART. 75.0% (95% CI 70.9–78.8%) of TB burden was recurrent
disease, but rates of new and recurrent TB did not differ
significantly (6.50 and 7.81 cases/100 PY respectively; IRR
1.20; 95% CI 0.96–1.50; p = 0.098). Rates calculated using only
culture-proven TB episodes did not differ significantly from the
overall rates. Culture-confirmed TB rates during the first, second,
third, fourth, fifth and beyond five years of ART were 9.86 (IRR
0.79; 95% CI 0.63–1.00), 4.49 (IRR 0.71; 95% CI 0.5–1.01), 4.39
(IRR 0.71; 95% CI 0.49–1.04), 5.57 (IRR 0.83; 95% CI 0.58–
1.21), 4.12 (IRR 0.76; 95% CI 0.48–1.18) and 4.16 (IRR 0.85;
95% CI 0.52–1.38) cases/100 PYs respectively.
TB incidence rates and updated CD4 cell counts
Person-time accrued within different updated CD4 cell count
strata was calculated (Figure 2). During the first year of ART
patients accrued more than 50% of time at CD4 cell counts ,200
cells/mL, compared to less than 5% of time beyond the fifth year of
ART. Time accrued at higher CD4 cell counts increased each
Table 1. Patient characteristics at initiation of antiretroviral therapy (ART).
Overall n =1544 No incident TB n=1120 Incident TB n=424 p-value
Mean age (years) 34.0 34.3 33.2 0.020
Gender Male 462 (29.9) 326 (29.1) 136 (32.1)
Female 1,082 (70.1) 794 (70.9) 288 (67.9) 0.256
WHO stage 1&2 305 (19.8) 237 (21.2) 68 (15.1)
3 861 (55.8) 625 (55.8) 236 (55.6) 0.049
4 378 (24.5) 258 (23.0) 120 (28.3)
Baseline CD4 cell count (cells/mL)a Median [IQR] 98 [48–155] 100 [47–157] 94 [48–149] 0.442
,50 375 (26.0) 272 (26.3) 103 (25.3)
50–99 349 (24.2) 241 (23.3) 108 (26.5)
100–149 321 (22.3) 225 (21.8) 96 (23.6) 0.314
$150 396 (27.5) 296 (28.6) 100 (24.6)
Baseline viral load (log10 copies/ml)
b Median [IQR] 4.87 [4.46–5.26] 4.86 [4.43–5.67] 4.88 [4.51–5.25] 0.598
,5 838 (58.7) 602 (58.7) 236 (58.7)
$5 590 (41.3) 424 (41.3) 166 (41.3) 0.991
Past history of TBc No 819 (53.0) 632 (56.4) 187 (44.1)
Yes 725 (47.0) 488 (43.6) 237 (55.9) ,0.001
Prevalent TBd No 1,080 (70.0) 757 (67.6) 323 (76.2)
Yes 464 (30.0) 363 (32.4) 101 (23.8) 0.001
Data are numbers (%) unless otherwise stated. ART, antiretroviral therapy; TB, tuberculosis; IQR, interquartile range.
aData missing for 103 patients.
bdata missing for 116 patients.
cincludes all TB episodes where anti-TB treatment was completed prior to ART enrolment.
dis TB episodes where patients are taking anti-TB treatment at ART initiation.
doi:10.1371/journal.pone.0034156.t001
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year after ART initiation, and over 50% of time accrued beyond
the fourth year of ART was spent at CD4 cell counts .500 cells/
mL.
TB incidence rates were then calculated by updated CD4
count strata (Table 3). Rates were highest during person-time
accrued with CD4 cells counts ,100 cells/mL at 25.49 cases/100
PYs (95% CI 21.57–30.33), decreasing to 2.70 cases/100 PYs
(95% CI 1.73–4.47) during person-time accrued in the highest
CD4 cell count category (.700 cells/mL). The median CD4
count in the .700 cells/mL stratum was 821 cells/mL.
Risk factors for incident TB
In the crude analysis (Table 4) updated CD4 cell counts
showed the strongest association with incident TB (p,0.001). TB
incidence was 9 times greater during person-time accrued at CD4
cell counts ,100 cells/mL compared person-time at CD4 cell
counts .700 cells/mL (IRR 9.45; 95% CI 5.78–15.42; p,0.001).
Viral loads .1000 copies/ml were associated with over three
times the risk of incident TB (IRR 3.34; 95% CI 2.78–4.01;
p,0.001). Duration of ART was also associated with incident TB
in crude analyses. Patients receiving ART for over 5 years were
60% less likely to be diagnosed with TB than during the first year
of ART (IRR 0.40; 95% CI 0.28–0.55; p,0.001). Of the baseline
characteristics, WHO stage at starting ART was associated with
increased risk of incident TB (IRR 1.64; 95% CI 1.24–2.15;
p = 0.002).
In a multivariate Poisson regression model, the updated CD4
cell count was the variable most strongly associated with the
development of incident TB during ART (Table 4). TB incidence
was nearly 7 times greater during person-time accrued at CD4 cell
counts ,100 cells/mL compared person-time at CD4 cell counts
.700 cells/mL (IRR 6.94; 95% CI 3.96–12.16; p,0.001).
Detection of a viral load $1000 copies/ml was also independently
associated with incident TB (IRR 1.74; 95% CI 1.39–2.17;
p,0.001) whereas duration of ART was not. Age and WHO stage
at ART enrolment were also independently associated with
development of incident TB during ART.
Comparison with community TB rates
In the local community 2922 TB episodes were notified during
289,304 PYs, giving an overall TB rate of 1.01 cases/100 PYs
(95% CI 0.97–1.04). The HIV uninfected population had 1262
TB episodes during an estimated 205,117 PYs, a rate of 0.62
cases/100 PYs (95% CI 0.58–0.65), less than 25% of the rate in
HIV-infected patients during person-time accrued at CD4 cell
counts .700 cells/mL (Figure 3). The proportion of cases in the
study cohort who were female was substantially greater than the
proportion in the community (70.1% versus 31.3%, respectively;
p,0.001), reflecting the typical ART cohort composition in sub-
Saharan Africa. Therefore TB incidence rates stratified by gender
and age were calculated and compared with ART patients with
similar characteristics in the study cohort and with updated CD4
counts .700 cells/mL. TB rates were 7 times higher in HIV-
infected women receiving ART aged 16–44 years compared to
uninfected women (2.70 and 0.37 cases/100PYs respectively; IRR
7.32; p,0.001) and 4 times higher in HIV-infected men receiving
ART aged 16–44 years compared to uninfected men in the same
local community (3.31 and 0.82 cases/100PYs respectively; IRR
4.01; p = 0.024).
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Discussion
The large size of this cohort, prolonged follow-up (median of 5.0
years), high rates of microbiological diagnosis and frequent CD4
count and viral load measurements allowed us to calculate with
greater precision than existing studies how long-term TB incidence
rates vary according to duration of ART and degree of CD4 cell
count recovery. Beyond the first year of ART, TB incidence rates
remained fairly constant, ranging between 6.71 and 4.92 cases/
100PYs, and TB risk was not associated with increasing duration
of ART in multivariate analysis. Instead, these data very clearly
confirm that TB risk over time is very strongly related to the
immunovirological response to ART. However, even when
patients’ CD4 cell counts exceeded a threshold of 700 cells/mL
and reached a median of 821 cells/mL, the TB incidence rate
remained more than 4-fold higher than the rate among HIV-
uninfected individuals living in the same community. These data
provide strong confirmatory evidence that long-term ART is not
associated with normalisation of TB risk even in those with
excellent CD4 cell count responses.
Several studies of TB incidence during ART have reported that
rates stabilise above the estimated background population rate
[12–14]. However, these analyses have lacked the appropriate
comparisons with rates among HIV-uninfected individuals of
similar age and gender living in the same community. In Cape
Town, introduction of provider-initiated testing and counselling in
2005 has resulted in dramatic increases in rates of HIV-testing
among TB patients [26]. For the first time, use of TB notification
data, patient HIV status and population denominators has made it
possible to derive estimates of TB incidence rates among the HIV-
infected and uninfected sub-populations in the city and by sub-
district [25]. In all comparisons of TB incidence rates stratified by
HIV-status, gender and age in this study, rates among HIV-
infected individuals attaining CD4 cell counts .700 cells/mL
during ART remained between 4 and 7-fold higher than the HIV-
uninfected comparison groups.
These data confirm that TB incidence rates even after 5 years of
ART remain high (approximately 5% per year) and a key
explanation for this was that approximately half the person-time
between 5 and 8 years of follow-up was accrued at CD4 cell counts
,500 cells/mL. The observation that rates even among those who
achieved CD4 cell counts .700 cells/mL remained much higher
than background is consistent with the hypothesis that ART is
insufficient to fully restore immune responses to Mycobacterium
tuberculosis [27]. This may be due to functional immune defects that
may persist despite excellent CD4 cell count recovery [27].
Another possibility that we cannot rule out is that individuals living
with HIV in this community have greater exposure to TB or other
common risk factors for the acquisition of both infections.
However, in communities such as this one with generalised HIV
and TB epidemics, this is a less likely explanation compared with
high income settings where epidemics are highly concentrated in
specific population sub-groups. We doubt that nosocomial TB
transmission is an important factor among healthy patients on
ART with CD4 cell counts .700 cells/mL, as such patients spend
relatively little time in health care settings and prevailing TB
transmission in the community is so high [28,29]. Further research
is warranted to investigate this excess TB risk despite good
response to ART.
Figure 2. Proportions of person-time accrued in updated CD4 cell count strata by duration of antiretroviral therapy (months) for
the whole study cohort.
doi:10.1371/journal.pone.0034156.g002
TB during Long-Term ART in South Africa
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e34156
This study also calculated rates of new and recurrent TB,
although we were unable to distinguish between recurrence due to
reinfection and endogenous reactivation of the original strain
(relapse). Studies in similar high-burden TB settings have
attributed most incident TB episodes to reinfection in the context
of HIV through molecular typing of mycobacterial isolates
[15,30,31]. Although recurrent TB was not associated with
increased TB risk in the multivariate analysis, high rates of
recurrent disease reflect high TB exposure and force of infection
this setting [32]. Recurrent disease accounted for 75% of the
burden of incident TB in this study, compared to 26% of the
overall and 43% of HIV-infected populations in Cape Town in
2009 [25]. This high proportion of recurrent disease may be
explained by the fact that TB is a key reason for initial
presentation to the health services and HIV diagnosis. Subsequent
prolonged survival during ART with persisting high TB risk means
that much of the subsequent incident TB is therefore recurrent.
Lack of viral load suppression was independently associated
with a higher risk of incident TB in this study. This association has
been noted in both developing and developed countries. Incident
TB during ART has also been associated with virological failure in
sub-Saharan African ART cohorts [33,34]. In vitro research has
shown HIV itself can cause functional impairment of anti-TB
immune response independently of loss CD4 cells [35]. However,
the temporal relationship between a detectable viral load during
ART and incident TB is less clearly defined.
The data from this study suggest that the greatly expanding
number of patients receiving long-term ART in high TB burden
settings represents a population with long-term heightened
susceptibility to TB. With an estimated 1 million people receiving
ART in South Africa in 2009, these patients would develop
approximately 50,000 episodes of TB each year long-term, and
this number will grow each year with ongoing ART scale-up [5].
This is a significant burden of disease that is a direct result of the
major increases in survival that are associated with ART. This
observation supports the conclusion that ART scale-up is likely to
have more limited impact on control of the HIV-associated TB
epidemic than might have been concluded from cohort studies of
the short-term impact of ART [2].
A number of interventions are needed to reduce the huge
burden of TB that we have described. Starting ART at higher
CD4 cell counts would reduce the person-time accrued at low
CD4 cell counts during which patients remain at high TB risk [2].
This, together with interventions to improve ART outcomes,
including improved adherence and reduced losses to follow-up,
will help increase ART’s impact on HIV-associated TB [2].
Second-line ART should be offered to patients with virological
failure as it is associated with improved immunological outcomes,
and hence a reduction in incident TB risk [36–38]. Intensified case
finding and implementation of other infection control interven-
tions are needed to reduce the risk of nosocomial TB transmission
[39]. Intensified screening at baseline expedites TB diagnosis and
is associated with substantial reductions in TB incidence rates
during the initial months of ART [40]. Serial screening at intervals
during ART might have additional impact._ENREF_49 Novel
diagnostics, such as the Xpert MTB/RIF assay and Determine
TB-LAM urine lipoarabinomannan antigen point-of-care assay
now provide the means for rapid screening of individuals within
the health care setting [41,42]. IPT and ART are interventions
that work via complementary mechanisms in the prevention of
HIV-associated TB [43]. Observational data show an additive
effect of IPT when used concurrently with ART, although
randomised control trials addressing this question directly are alsoT
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underway such as one in South Africa (http://clinicaltrials.gov/
ct2/show/NCT00463086) [43–46].
The observational design of this study has inherent limitations,
but may also improve generalizability as our programmatic
conditions will be similar to other ART clinics. However, the
HIV-infected cohort potentially had better access to healthcare
services compared to the HIV-uninfected population and
therefore there may have been differences in case ascertainment
between the two. There were some biological and social risk
factors we were unable to account for in this study, for example
diabetes and smoking. These factors alone are unlikely to account
for the discrepancy in TB rates between the HIV-uninfected
population and persons reaching the highest CD4 cell counts.
Although high, our rates of non-death losses are similar to other
South African studies, and probably reflect the highly mobile
population of the Cape townships [47,48]. Anti-TB treatment
completion could not be confirmed for TB episodes treated prior
to ART programme enrolment, but any inadequately treated TB
is likely to have been diagnosed during pre-ART screening. In the
absence of post-mortem studies, we were unable to determine the
proportion of deaths that were associated with unascertained TB.
Strengths of this study include over twice the median follow-up
of any study of comparable size assessing TB incidence during
ART. The baseline characteristics, immune recovery and
outcomes in this cohort were comparable to other ART cohorts
from sub-Saharan Africa [7–10,49]. Although data were from a
single site in a community with TB rates that are likely to be higher
than communities elsewhere in sub-Saharan Africa, the relation-
Table 4. Univariate and multivariate analyses of risk factors for incident tuberculosis (TB) during antiretroviral therapy.
Crude analysis Multivariate analysisf
IRR 95% CI p-value IRR 95% CI p-value
Age at enrolmenta 0.99 0.98–1.00 0.081 0.98 0.97–1.00 0.008
Gender M 1 1
F 1.09 0.91–1.31 0.357 0.98 0.80–1.19 0.860
WHO stage at enrolment 1 & 2 1 1
3 1.35 1.06–1.74 0. 002 1.26 0.97–1.65 0.018
4 1.64 1.24–2.15 1.56 1.15–2.10
Baseline CD4 cell count (cells/mL)b ,50 1
50–99 0.98 0.76–1.25
100–149 1.01 0.78–1.31 0.258
$150 0.81 0.63–1.04
Baseline viral load (log10 copies/ml)
c ,5 1
$5 1.03 0.85–1.23 0.780
Duration of ART (months) 0–12 1 1
12–24 0.54 0.42–0.70 1.01 0.76–1.33
24–36 0.49 0.38–0.65 1.08 0.79–1.46
36–48 0.53 0.41–0.70 ,0.001 1.25 0.92–1.69 0.812
48–60 0.44 0.32–0.60 1.10 0.79–1.55
.60 0.40 0.28–0.55 1.05 0.73–1.52
Updated CD4 cell count (cells/mL)d .700 1 1
501–700 1.50 0.89–2.53 1.56 0.92–2.63
401–500 1.87 1.10–3.21 1.96 1.14–3.39
301–400 1.86 1.10–3.14 ,0.001 1.96 1.16–3.33 ,0.001
201–300 2.91 1.76–4.83 2.97 1.75–5.01
101–200 4.16 2.53–6.85 3.81 2.24–6.46
0–100 9.45 5.78–15.42 6.94 3.96–12.16
Updated viral load (copies/ml)d ,1000 1 1
$1000 3.34 2.78–4.01 ,0.001 1.74 1.39–2.17 ,0.001
Recurrent TBe No 1 1
Yes 1.20 0.96–1.50 0.098 1.04 0.82–1.31 0.763
ART, antiretroviral therapy; TB, tuberculosis; IRR, incident rate ratio; CI, confidence interval. All p-values were calculated using the likelihood ratio test. There were no
interactions between variables in the multivariate analysis.
aAge is included as continuous variable, the IRR represents a 1 year increase in age.
bMeasurement taken at ART enrolment, data missing for 103 patients.
cMeasurement taken at ART enrolment, data missing for 116 patients.
dCD4 cell counts and viral load are time-updated variables using serial measurements taken during ART.
eAny previous episodes of TB, including prior to ART enrolment, a time-updated variable.
fdata for all 1544 patients included in final model.
doi:10.1371/journal.pone.0034156.t004
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ship between incident TB, response to ART and comparisons to
background rates that we have carefully documented are likely to
be applicable to other settings. Over 73% of cases were
microbiologically proven and availability of routine mycobacterial
culture greatly enhanced the reliability of TB diagnoses. Routine
monitoring of CD4 cell count and viral load every four months
provided accurate information on time-updated immunovirologi-
cal responses. The availability of an electronic TB register, high
rates of HIV-testing in TB patients in Cape Town and use of
population denominators allowed us to calculate TB rates specific
to the sub-district where the ART clinic was based.
In conclusion, TB incidence rates during long-term ART
remained substantially greater than rates in the local HIV
uninfected populations regardless of prolonged duration of ART
or attainment of CD4 cell counts exceeding 700 cells/mL. With
ongoing rapid expansion of ART, TB developing in patients
receiving long-term ART will represent an increasing burden of
disease that requires additional interventions to control.
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